MARKET

AKER

AKER

Akers
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.850
-0.100
-5.13%
After Hours: 1.850 0 0.00% 19:32 10/30 EDT
OPEN
1.950
PREV CLOSE
1.950
HIGH
1.952
LOW
1.800
VOLUME
260.26K
TURNOVER
--
52 WEEK HIGH
9.84
52 WEEK LOW
1.550
MARKET CAP
16.14M
P/E (TTM)
-0.3430
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
VBIV, DGLY, OPK and QDEL among midday movers
Gainers: VBI Vaccines (VBIV) +35%.Rekor Systems (REKR) +24%.BMC Stock (BMCH) +22%.Digital Ally (DGLY) +22%.Innodata (INOD) +21%.Rhythm Pharmaceuticals (RYTM) +21%.IZEA Worldwide (IZEA) +17%.AutoWeb (AUTO) +17%.TFF Pharmaceuticals (TFFP) +13%.China Liberal Education (CLEU) +10%.Losers: Quidel
Seekingalpha · 08/27 16:41
Akers Biosciences down 28% on early data on COVID-19 vaccine candidate
Nano cap Akers Biosciences ([[AKER]] -28.1%) slumps on more than a 5x surge in volume in reaction to proof-of-concept data from animal studies assessing the safety and immunogenicity of its
Seekingalpha · 08/27 16:38
VBI Vaccines and Amarin among healthcare gainers; Quidel leads the losers
Gainers: VBI Vaccines VBIV +53%. AIM ImmunoTech AIM +13%. Rhythm Pharmaceuticals (RYTM) +10%. Amarin (AMRN) +9%. Tenet Healthcare (THC) +7%.Losers: Quidel QDEL -37%. Fluidigm (FLDM) -31%. Akers Biosciences (AKER) -31%. Fulgent Genetics (FLGT) -28%. Aptorum
Seekingalpha · 08/27 15:03
Akers Biosciences and Premas Biotech Announce SARS CoV-2 Proof of Concept Results
Thorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the "Company") (NASDAQ:AKER), a developer of rapid health information technologies, today announced with its partner, Premas
Benzinga · 08/27 13:01
GEVO, GME, TOPS and BKE among midday movers
Gainers: Hancock Jaffe Laboratories (NASDAQ:HJLI) +127%. Harpoon Therapeutics (NASDAQ:HARP) +38%. ShiftPixy (NASDAQ:PIXY) +22%. Velocity Financial (NYSE:VE
Seeking Alpha - Article · 08/21 16:43
Hancock Jaffe Laboratories leads healthcare gainers: Organovo leads the losers
Gainers: Hancock Jaffe Laboratories (HJLI) +83%. Bio-Path Holdings (BPTH) +22%. Harpoon Therapeutics (HARP) +21%. Fluidigm (FLDM) +15%. Midatech Pharma (MTP) +13%.Losers: Organovo (ONVO) -10%. Akers Biosciences (AKER) -9%. Trevena (TRVN) -9%. OpGen (OPGN) -9%. Axcella Health
Seekingalpha · 08/21 15:03
Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
GlobeNewswire · 08/11 13:00
Akers Biosciences shares are trading lower after the company announced a 1.207 million share common stock offering at $5.67 per share.
Benzinga · 08/11 12:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKER. Analyze the recent business situations of Akers through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKER stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 647.10K
% Owned: 7.42%
Shares Outstanding: 8.72M
TypeInstitutionsShares
Increased
0
0
New
2
37.00K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.96%
Healthcare Equipment & Supplies
-0.92%
Key Executives
Chairman/President/Executive Director
Christopher Schreiber
Chief Executive Officer/Director
.. Gormally
Chief Financial Officer
Stuart Benson
Lead Director/Independent Director
Joshua Silverman
Independent Director
Robert Schroeder
Independent Director
Bill White
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AKER
Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company’s product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin and for on- and off-the-job alcohol safety initiatives. The Company's primary focus is on the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Akers Biosciences Inc stock information, including NASDAQ:AKER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKER stock methods without spending real money on the virtual paper trading platform.